Showing 4341-4350 of 7324 results for "".
- New Research Highlights Need for Greater Sun Safety Educationhttps://practicaldermatology.com/news/new-research-highlights-need-for-greater-sun-safety-education/2458261/Taken together, two new studies provide a mixed bag of news on the effectiveness of public health measures and messages aimed at decreasing skin cancer risk and improving sun safety behaviors. One study show
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- New From Skinceuticals: H.A. Intensifierhttps://practicaldermatology.com/news/new-from-skinceuticals-ha-intensifier/2458285/SkinCeuticals is rolling out their new H.A. Intensifier, a corrective hyaluronic acid serum. Key ingredients include 10% Proxylane, a proprietary ingredient, to support hyaluronic acid levels and
- Hologic to Acquire Cynosurehttps://practicaldermatology.com/news/hologic-to-acquire-cynosure/2458288/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billi
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- ZO Skin Health Introduces Oraser Cellulite Control Creamhttps://practicaldermatology.com/news/zo-skin-health-introduces-oraser-cellulite-control-cream/2458295/ZO Skin Health's new Oraser Cellulite Control is formulated to offer instant firming effects, visibly improve the skin's texture, and reduce the appearance of cellulite. In addition to smoothing skin and diminishing the "orange peel" appearance, the crème also helps impro
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only
- Venus Concept Launches Venus Velocity for Laser Hair Removalhttps://practicaldermatology.com/news/venus-concept-launches-venus-velocity-for-laser-hair-removal/2458314/Venus Concept is bringing a new hair removal laser to the US. Venus Velocity is a diode laser for hair removal, permanent hair reduction, and the treatment of razor bumps. The device has two modes of operation (SLIDE and PULSE), three changeable s
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans